Vedolizumab, a monoclonal antibody to the gut homing 01.4137 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

被引：58

作者：

Milch, Catherine ^{[1
]}

Wyant, Tim ^{[1
]}

Xu, Jing ^{[1
]}

Parikh, Asit ^{[2
]}

Kent, Whitney ^{[1
]}

Fox, Irving ^{[1
]}

Berger, Joseph ^{[3
]}

机构：

[1] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Takeda Pharmaceut Int Inc, Deerfield, IL 60015 USA

[3] Univ Kentucky, Dept Neurol, Coll Med, Kentucky Clin, Lexington, KY 40536 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2013年 / 264卷 / 1-2期

关键词：

Vedolizumab; Inflammatory bowel disease; Cerebrospinal fluid; Immune surveillance; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; MAINTENANCE THERAPY; NATALIZUMAB; ALPHA(4)BETA(7); ANTAGONISM; INDUCTION;

D O I：

10.1016/j.jneuroim.2013.08.011

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vedolizumab, a gut-homing ot4137 integrin antagonist, has demonstrated efficacy in ulcerative colitis and Crohn's disease. Development of progressive multifocal leukoencephalopathy, a serious brain infection associated with natalizumab (an ot437 and 0t4(2,1 integrin antagonist), has raised concern that vedolizumab may convey a similar risk. Natalizumab is believed to impair central nervous system immune surveillance by affecting cerebrospinal fluid (CSF) lymphocyte counts and the CD4:CD8 ratio. To determine if vedolizumab elicits similar effects, we examined CSF of healthy volunteers by flow cytometry for T-lymphocyte surface markers 5 weeks after administration of intravenous vedolizumab 450 mg. No significant changes were observed in CSF T-lymphocyte populations. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：123 / 126

页数：4

共 15 条

[1]

[Anonymous], 2011, TYSABRI NAT PACK INS

[2] Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences [J].